Overall, these orthogonal approaches indicate uterine tumors with ACTG1 gains have repressed IFN-γ and lymphocyte infiltration, which suggests these tumors may exhibit differential responses towards innate immunity or even immunotherapies. The gene discussed is IFNG; the disease is tumor of uterus.